title: Zinostatin stimalamer-transcatheter arterial embolization for hepatocellular carcinoma: a comparison with lipiodol-transcatheter arterial embolization.
abstract: Twenty patients with unresectable hepatocellular carcinoma were treated by zinostatin stimalamer-transcatheter arterial embolization (SMANCS-TAE). After administration of SMANCS, a superselective catheterization technique was used to inject gelatin sponge particles into the artery or artery branch supplying the cancer-bearing segment. We compared the results of SMANCS-TAE with Lipiodol (Yamanouchi, Tokyo, Japan)-TAE performed during the same period. In 18 of 20 patients (90%), a tumor necrosis rate of 100% (grade 4) was obtained after one or two courses of SMANCS-TAE. The SMANCS group was superior to the Lipiodol-TAE group in terms of the tumor reduction rate, alpha-fetoprotein reduction rate, and cumulative 1.5-year survival rate, but not significantly. No severe side effects were noted after SMANCS-TAE. SMANCS-TAE appears to have potential as a new treatment for hepatocellularcarcinoma, and patients treated with this technique will be monitored to elucidate the long-term effects.
authors.affiliation: Department of Gastroenterology, Chukyo Hospital, Minami-ku, Nagoya Japan.
authors.forename: N
authors.initials: N
authors.lastname: Hirashima
authors.forename: K
authors.initials: K
authors.lastname: Sakakibara
authors.forename: I
authors.initials: I
authors.lastname: Itazu
authors.forename: T
authors.initials: T
authors.lastname: Hirai
authors.forename: A
authors.initials: A
authors.lastname: Nemoto
authors.forename: H
authors.initials: H
authors.lastname: Matsuura
authors.forename: K
authors.initials: K
authors.lastname: Kumada
authors.forename: O
authors.initials: O
authors.lastname: Nojiri
authors.forename: H
authors.initials: H
authors.lastname: Kano
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004317:Doxorubicin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy*; D008297:Male; D008299:Maleic Anhydrides / Q000008:administration & dosage*; D008875:Middle Aged; D011137:Polystyrenes / Q000008:administration & dosage*; D011859:Radiography; D015996:Survival Rate; D009353:Zinostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000903:Antibiotics, Antineoplastic; D008299:Maleic Anhydrides; D011137:Polystyrenes; C035755:poly(maleic acid-styrene)neocarzinostatin; D015251:Epirubicin; D007459:Iodized Oil; D004317:Doxorubicin; D009353:Zinostatin